Deal of The Day! Hurry Up, Grab the Special Discount - Save 25% - Ends In 00:00:00 Coupon code: SAVE25
Welcome to Pass4Success

- Free Preparation Discussions
Mail Us support@pass4success.com
Location US
Mob_nav_barsMENU

CIPS L4M6 Exam - Topic 3 Question 64 Discussion

[Partnership and collaboration models]Grey Stone Memorial Hospital is a private medical facility which has an idea for a vaccine to a deadly disease, but does not have the capacity to make the vaccine itself. It is considering partnering with a well-known pharmaceutical company in order to bring the vaccine to market. What is the biggest risk to Grey Stone?
A) Intellectual Property Rights
B) Increased Costs
C) Low quality product
D) Uninformed stakeholders

CIPS L4M6 Exam - Topic 3 Question 64 Discussion

Actual exam question for CIPS's L4M6 exam
Question #: 64
Topic #: 3
[All L4M6 Questions]

[Partnership and collaboration models]

Grey Stone Memorial Hospital is a private medical facility which has an idea for a vaccine to a deadly disease, but does not have the capacity to make the vaccine itself. It is considering partnering with a well-known pharmaceutical company in order to bring the vaccine to market. What is the biggest risk to Grey Stone?

Show Suggested Answer Hide Answer
Suggested Answer: A

by Lovetta at Jun 16, 2025, 05:07 PM

Limited Time Offer

25%

Off

Get Premium L4M6 Questions as Interactive Web-Based Practice Test or PDF

Contribute your Thoughts:

0/2000 characters
Submit Cancel
Trina
9 months ago
Wait, uninformed stakeholders could really derail this?
upvoted 0 times
...
Viola
9 months ago
I think increased costs are a bigger concern.
upvoted 0 times
...
Shelia
9 months ago
Totally agree with the IP rights risk!
upvoted 0 times
...
Lenita
9 months ago
Low quality product? That’s a real possibility!
upvoted 0 times
...
Nakisha
9 months ago
Intellectual property rights can be a huge risk in partnerships.
upvoted 0 times
...
Tonja
10 months ago
Uninformed stakeholders could definitely pose a problem, but I think the intellectual property rights issue might overshadow that in this scenario.
upvoted 0 times
...
Catarina
10 months ago
I feel like the quality of the product is crucial, but I don't know if that's the biggest risk. We talked about quality control in similar practice questions.
upvoted 0 times
...
Bulah
10 months ago
I'm not entirely sure, but I think increased costs could be a risk too. If the pharmaceutical company raises prices, it might affect Grey Stone's budget.
upvoted 0 times
...
Tegan
10 months ago
I remember discussing how intellectual property rights can be a major concern in partnerships, especially when sharing proprietary information.
upvoted 0 times
...
Anabel
10 months ago
Low quality product is an interesting option. If the hospital doesn't have full control over the manufacturing process, there's a risk the vaccine could end up being subpar. I'll have to weigh that against the other choices.
upvoted 0 times
...
Darci
11 months ago
Increased costs seems like the most likely answer here. Partnering with a big pharma company is going to come with a lot of overhead and fees that could really eat into the hospital's profits.
upvoted 0 times
...
Lashon
11 months ago
Hmm, I'm not sure about this one. There are a few potential risks to consider. I think I need to think through the different partnership models and how they could impact the hospital's position.
upvoted 0 times
...
Jolene
11 months ago
This seems like a pretty straightforward question. The biggest risk is probably intellectual property rights - the hospital might lose control of the vaccine formula if they partner with the pharmaceutical company.
upvoted 0 times
...
Cherelle
1 year ago
I agree, the IP rights are crucial. They better get a good lawyer to draw up that contract!
upvoted 0 times
Clarence
11 months ago
A) Intellectual Property Rights
upvoted 0 times
...
Lenny
11 months ago
D) Uninformed stakeholders
upvoted 0 times
...
Boris
11 months ago
C) Low quality product
upvoted 0 times
...
Maile
11 months ago
B) Increased Costs
upvoted 0 times
...
Sue
12 months ago
A) Intellectual Property Rights
upvoted 0 times
...
Merri
12 months ago
D) Uninformed stakeholders
upvoted 0 times
...
Bernardine
12 months ago
C) Low quality product
upvoted 0 times
...
Queenie
12 months ago
B) Increased Costs
upvoted 0 times
...
Lang
1 year ago
A) Intellectual Property Rights
upvoted 0 times
...
...
Isadora
1 year ago
Uninformed stakeholders? That's a good one. How about 'Disgruntled shareholders who can't get their hands on the vaccine first'?
upvoted 0 times
...
Gilberto
1 year ago
Low quality product is a risk too. They need to ensure the pharma company can manufacture the vaccine to their standards.
upvoted 0 times
Francene
1 year ago
B) Increased Costs
upvoted 0 times
...
Rebecka
1 year ago
A) Intellectual Property Rights
upvoted 0 times
...
...
Alverta
1 year ago
But what about B) Increased Costs? Partnering with a big company could lead to unexpected expenses for Grey Stone.
upvoted 0 times
...
Quiana
1 year ago
I agree with Eric. If they partner with a pharmaceutical company, they might lose control over their vaccine's intellectual property.
upvoted 0 times
...
Eric
1 year ago
I think the biggest risk to Grey Stone is A) Intellectual Property Rights.
upvoted 0 times
...
Arlette
1 year ago
Increased Costs could also be a major concern. The partnership might end up costing more than Grey Stone expected.
upvoted 0 times
...
Willis
1 year ago
I think the biggest risk to Grey Stone is Intellectual Property Rights. They need to make sure their vaccine formula is protected before partnering with the pharma company.
upvoted 0 times
Veronika
1 year ago
C) Low quality product
upvoted 0 times
...
Elke
1 year ago
B) Increased Costs
upvoted 0 times
...
Freeman
1 year ago
A) Intellectual Property Rights
upvoted 0 times
...
...

Save Cancel